IBA reports strong Half Year 2025 results, transforming towards a more profitable business

Louvain-la-Neuve, Belgium, 28 August 2025 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its consolidated results for the first half of 2025.

High revenue growth and improved profitability in H1 driven by accelerated backlog conversion

• Net sales rose 40% vs. H1 2024, to EUR 304.9 million, with IBA Clinical and IBA Technologies increasing by 47% and 30% respectively thanks to well-executed backlog conversion
• Gross margin decreased to 29.5% vs. 32.6% in H1 2024, driven by less favorable equipment profitability mix (including legacy low-margin projects in Proton Therapy) partially offset by productivity improvements
• REBIT stood at EUR 10.6 million vs. EUR 0.0 million in H1 2024 with OPEX under control at 26% of total net sales and IBA Clinical achieving break-even REBIT
• Net loss of EUR 2.6 million reflecting targeted, non-recurring expenses such as the migration to a new ERP system , and foreign exchange fluctuations (primarily EUR/USD)